Diagnosis uses consensus criteria (MSIS/ICM) combining major and minor criteria. Classify by timing: early (24 mo) — guides biofilm maturity and strategy. Treatment options: DAIR (debridement, antibiotics, implant retention), one‑stage or two‑stage revision; chronic suppression in poor hosts. Principles: radical debridement, exchange modular parts, biofilm‑active antibiotics (e.g., rifampicin combinations for staph). Prevention bundle: laminar flow, antibiotic prophylaxis, skin prep, glycemic control, normothermia.
Which of the following is a major criterion for diagnosing periprosthetic joint infection according to the Musculoskeletal Infection Society (MSIS) criteria?
What is the recommended treatment strategy for an early periprosthetic joint infection (
Which of the following antibiotics is particularly effective against biofilms associated with Staphylococcus species in periprosthetic joint infection?
What is the classification of periprosthetic joint infections that occur more than 24 months after arthroplasty?
Which of the following factors is NOT a recognized risk factor for periprosthetic joint infection?
What is the primary benefit of optimizing glycemic control in patients undergoing joint arthroplasty?
Which of the following is NOT part of the prevention bundle for periprosthetic joint infection?
Which imaging modality is most useful for detecting implant loosening in suspected periprosthetic joint infection?
In periprosthetic joint infection, the presence of which of the following in synovial fluid analysis is most indicative of infection?
Which of the following is a common organism responsible for chronic periprosthetic joint infections?
